361 related articles for article (PubMed ID: 24275632)
1. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.
Steinberg BA; Holmes DN; Piccini JP; Ansell J; Chang P; Fonarow GC; Gersh B; Mahaffey KW; Kowey PR; Ezekowitz MD; Singer DE; Thomas L; Peterson ED; Hylek EM;
J Am Heart Assoc; 2013 Nov; 2(6):e000535. PubMed ID: 24275632
[TBL] [Abstract][Full Text] [Related]
2. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
Steinberg BA; Kim S; Piccini JP; Fonarow GC; Lopes RD; Thomas L; Ezekowitz MD; Ansell J; Kowey P; Singer DE; Gersh B; Mahaffey KW; Hylek E; Go AS; Chang P; Peterson ED;
Circulation; 2013 Aug; 128(7):721-8. PubMed ID: 23861512
[TBL] [Abstract][Full Text] [Related]
3. Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II).
Steinberg BA; Shrader P; Pieper K; Thomas L; Allen LA; Ansell J; Chan PS; Ezekowitz MD; Fonarow GC; Freeman JV; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli GV; Reiffel JA; Singer DE; Peterson ED; Piccini JP;
J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29453305
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Graham DJ; Reichman ME; Wernecke M; Zhang R; Southworth MR; Levenson M; Sheu TC; Mott K; Goulding MR; Houstoun M; MaCurdy TE; Worrall C; Kelman JA
Circulation; 2015 Jan; 131(2):157-64. PubMed ID: 25359164
[TBL] [Abstract][Full Text] [Related]
5. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
Zalesak M; Siu K; Francis K; Yu C; Alvrtsyan H; Rao Y; Walker D; Sander S; Miyasato G; Matchar D; Sanchez H
Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):567-74. PubMed ID: 23922182
[TBL] [Abstract][Full Text] [Related]
6. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
Abraham NS; Singh S; Alexander GC; Heien H; Haas LR; Crown W; Shah ND
BMJ; 2015 Apr; 350():h1857. PubMed ID: 25910928
[TBL] [Abstract][Full Text] [Related]
7. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
Eikelboom JW; Wallentin L; Connolly SJ; Ezekowitz M; Healey JS; Oldgren J; Yang S; Alings M; Kaatz S; Hohnloser SH; Diener HC; Franzosi MG; Huber K; Reilly P; Varrone J; Yusuf S
Circulation; 2011 May; 123(21):2363-72. PubMed ID: 21576658
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
[TBL] [Abstract][Full Text] [Related]
9. Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: a retrospective claims analysis.
AbuDagga A; Stephenson JJ; Fu AC; Kwong WJ; Tan H; Weintraub WS
BMC Health Serv Res; 2014 Jul; 14():310. PubMed ID: 25034699
[TBL] [Abstract][Full Text] [Related]
10. Patterns of oral anticoagulants use in atrial fibrillation.
Brais C; Larochelle J; Turgeon M; Tousignant A; Blais L; Perreault S; Farand P; Letemplier G; Beauchesne M
J Popul Ther Clin Pharmacol; 2015; 22(1):e90-5. PubMed ID: 25715385
[TBL] [Abstract][Full Text] [Related]
11. Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
Cullen MW; Kim S; Piccini JP; Ansell JE; Fonarow GC; Hylek EM; Singer DE; Mahaffey KW; Kowey PR; Thomas L; Go AS; Lopes RD; Chang P; Peterson ED; Gersh BJ;
Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):461-9. PubMed ID: 23759473
[TBL] [Abstract][Full Text] [Related]
12. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.
Oldgren J; Alings M; Darius H; Diener HC; Eikelboom J; Ezekowitz MD; Kamensky G; Reilly PA; Yang S; Yusuf S; Wallentin L; Connolly SJ;
Ann Intern Med; 2011 Nov; 155(10):660-7, W204. PubMed ID: 22084332
[TBL] [Abstract][Full Text] [Related]
13. Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
Steinberg BA; Kim S; Thomas L; Fonarow GC; Hylek E; Ansell J; Go AS; Chang P; Kowey P; Gersh BJ; Mahaffey KW; Singer DE; Piccini JP; Peterson ED;
Circulation; 2014 May; 129(20):2005-12. PubMed ID: 24682387
[TBL] [Abstract][Full Text] [Related]
14. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
Eikelboom JW; Connolly SJ; Hart RG; Wallentin L; Reilly P; Oldgren J; Yang S; Yusuf S
J Am Coll Cardiol; 2013 Sep; 62(10):900-8. PubMed ID: 23770182
[TBL] [Abstract][Full Text] [Related]
15. National trends in oral anticoagulant use in the United States, 2007 to 2011.
Kirley K; Qato DM; Kornfield R; Stafford RS; Alexander GC
Circ Cardiovasc Qual Outcomes; 2012 Sep; 5(5):615-21. PubMed ID: 22949490
[TBL] [Abstract][Full Text] [Related]
16. Temporal Trends in the Use and Comparative Effectiveness of Direct Oral Anticoagulant Agents Versus Warfarin for Nonvalvular Atrial Fibrillation: A Canadian Population-Based Study.
Yu AYX; Malo S; Svenson LW; Wilton SB; Hill MD
J Am Heart Assoc; 2017 Oct; 6(11):. PubMed ID: 29080863
[TBL] [Abstract][Full Text] [Related]
17. Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran.
Vaughan Sarrazin MS; Jones M; Mazur A; Chrischilles E; Cram P
Am J Med; 2014 Dec; 127(12):1179-85. PubMed ID: 25107386
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
Hijazi Z; Hohnloser SH; Oldgren J; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Reilly PA; Siegbahn A; Yusuf S; Wallentin L
Circulation; 2014 Mar; 129(9):961-70. PubMed ID: 24323795
[TBL] [Abstract][Full Text] [Related]
19. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
Chan KE; Edelman ER; Wenger JB; Thadhani RI; Maddux FW
Circulation; 2015 Mar; 131(11):972-9. PubMed ID: 25595139
[TBL] [Abstract][Full Text] [Related]
20. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.
Pisters R; Nieuwlaat R; Lane DA; Crijns HJ; Lip GY
Thromb Haemost; 2013 Feb; 109(2):328-36. PubMed ID: 23179181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
